Ostia Sciences Analysis: $2M Raised
What is Ostia Sciences?
Biotech startup developing microbiome-based therapeutics
Product Features & Capabilities
- Salivaricin 10
- Streptococcus salivarius SALI-10
- Pipeline of microbiome therapies
- Health indications for disease prevention
Use Cases
Combat oral and respiratory infections with Salivaricin 10; Regulate immune responses using proprietary probiotics; Develop new antibiotic-like molecules through bacteriocin production; Characterize microbiome states in health and disease; Enhance therapeutic activity against infections
Other Considerations
Secured over $1 million CAD in seed investment; Finalized IP assignment with the University of Toronto; Developed first prototype for microbiome technology
See something that needs updating? Suggest edits to this profile.